Analysis Of Income And Expense [Abstract]

Pharming Group N.V. - Filing #1859781

Concept	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	—	—	—	—	198,871,000 USD	—	—	—	212,174,000 USD	—	—	—	—	—
Material income and expense [abstract]
Research and development expense	—	—	—	—	—	—	70,369,000 USD	—	—	—	38,519,000 USD	—	—	—	—	—
Finance income (cost)	—	—	—	—	—	—	8,823,000 USD	—	—	—	32,524,000 USD	—	—	—	—	—
Sales and marketing expense	—	—	—	—	—	—	59,445,000 USD	—	—	—	51,604,000 USD	—	—	—	—	—
Gains (losses) on change in fair value of derivatives [abstract]
Gains (losses) on change in fair value of derivatives	—	—	—	—	—	—	114,000 USD	—	—	—	69,000 USD	—	—	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	—	—	—	—	—	14,802,000 USD	—	—	—	14,956,000 USD	—	—	—	—	—
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Share of profit (loss) of associates accounted for using equity method	—	—	—	—	—	—	694,000 USD	—	—	—	362,000 USD	—	—	—	—	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	— USD	270,000 USD	— USD	15,072,000 USD	— USD	2,283,000 USD	1,089,000 USD	15,996,000 USD	37,746,000 USD	— USD	52,702,000 USD	14,956,000 USD	— USD	— USD	— USD	— USD